|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, an increasing number of TFE3 rearrangement-associated tumours have been reported, such as TFE3 rearrangement-associated perivascular epithelioid cell tumours (PEComas), melanotic Xp11 translocation renal cancers and melanotic Xp11 neoplasms.
|
26844676 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PEComas constitute a genetically diverse group that includes neoplasms harboring TFE3 gene rearrangements and those with TSC2 mutations, indicating alternative tumorigenic pathways.
|
26144278 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To evaluate the feasibility and efficacy of tumor enucleation (TE) for patients with small renal cell carcinoma (RCC) associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC) by analyzing the pseudocapsule characteristics of Xp11.2 RCCs comparing with that of clear cell renal cell carcinoma (ccRCC).
|
26191243 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
One TFE3-negative tumour with polysomy 7/17 but normal VHL was diagnosed as papillary RCC, and two with normal chromosomes 7/17 and VHL gene were considered unclassifiable.
|
25544614 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our data suggest that these tumors belong to a single clinicopathologic spectrum and expand the known characteristics of TFE3 rearrangement-associated tumors.
|
26274027 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combined RNA sequencing and fluorescence in situ hybridization analysis identified 9 (23%) TFE3 gene-rearranged tumors, with 3 cases showing an SFPQ/PSF-TFE3 fusion and 1 case showing a novel DVL2-TFE3 gene fusion.
|
25651471 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
TFE3 translocation-associated perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis.
|
25517951 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This translocation is diagnostically useful because the tumor nuclei are positive for TFE3 by immunohistochemistry.
|
26516944 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our TFE3 FISH assay is a useful adjunct to morphologic analysis of such challenging cases and will be applicable to assess the growing spectrum of TFE3-rearranged tumors.
|
23828314 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Kidney-specific cadherin, cytokeratin 34betaE12 and TFE3 stains were negative in the tumor.
|
24702883 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the tumor demonstrated moderately (2+) or strongly (3+) positive staining for TFEB, Cathepsin K, Ksp-cadherin, and vimentin but negative for TFE3, CD10, HMB45, melan A, CKpan, and CK7.
|
23826432 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Malignant perivascular epithelioid cell neoplasm (PEComa) of the urinary bladder with TFE3 gene rearrangement: clinicopathologic, immunohistochemical, and molecular features.
|
23797724 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Seventeen cases showed TFE3 rearrangement associated with Xp11.2 translocation by FISH, including all 13 tumors with moderate or strong TFE3 (n=10) or cathepsin K (n=7) immunoreactivity.
|
23598965 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.
|
24339735 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Various gene fusions including the transcription factor E3 (TFE3) gene located on chromosome X cause the tumor.
|
23760492 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
If reproducible using immunohistochemistry (IHC), this finding would have important implications for pathologists in the diagnosis of Xp11.2 RCC, calling into question the specificity of nuclear immunoreactivity for TFE3 in these tumors.
|
23628822 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results also suggest that adult RCC with TFE3 rearrangement may be a clinically aggressive tumor.
|
22498819 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As the true frequency of these neoplasms as well as the biological properties of TFE3 activation in renal cell carcinomas are largely unknown, we have examined TFE3 expression as well as the underlying genetic alterations in a large, hospital-based series of renal cell carcinomas with long-term follow-up information.
|
22037260 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The concordance between expression measures derived from ASPS-1 and both pooled and individual patient tumor data provided a rationale for extending the analysis to include patient ASPL-TFE3 fusion transcript data.
|
23226201 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a result, 5 tumors showed a positive reaction for TFE3 with a range from 1+ to 2+ in intensity.No tumors were positive for TFEB.
|
21424937 |
2011 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These cells grew slowly and were expanded over a period of 3 years and have maintained characteristics consistent with those of both the original ASPS tumor from the patient and the xenograft tumor including (1) presence of the alveolar soft part locus-transcription factor E3 type 1 fusion transcript and nuclear expression of the alveolar soft part locus-transcription factor E3 type 1 fusion protein; (2) maintenance of the t(X;17)(p11;q25) translocation characteristic of ASPS; and (3) expression of upregulated ASPS transcripts involved in angiogenesis (ANGPTL2, HIF-1-α, MDK, c-MET, VEGF, and TIMP-2), cell proliferation (PRL, PCSK1), metastasis (ADAM9), as well as the transcription factor BHLHB3 and the muscle-specific transcripts TRIM63 and ITGβ1BP3.
|
21552147 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Two tumors with ASPL-TFE3 gene fusion also showed TFE3 over-expression.
|
21070573 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TFE3 and Cathepsin K remain the most sensitive and specific markers of these neoplasms.
|
20679884 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, aberrant immunoreactivity for TFE3 protein (a sensitive and specific marker of neoplasms harboring TFE3 gene fusions) has been reported in as many as 100% of PEComas; however, TFE3 gene status in these neoplasms has not been systematically investigated.
|
20871214 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Diagnostic tools to detect translocations involving the TFE3 gene on chromosome X would be valuable in the evaluation of these tumors.
|
20421778 |
2010 |